Search Results - "Erion, Mark D"

Targeting a ceramide double bond improves insulin resistance and hepatic steatosis by Chaurasia, Bhagirath, Tippetts, Trevor S, Mayoral Monibas, Rafael, Liu, Jinqi, Li, Ying, Wang, Liping, Wilkerson, Joseph L, Sweeney, C Rufus, Pereira, Renato Felipe, Sumida, Doris Hissako, Maschek, J Alan, Cox, James E, Kaddai, Vincent, Lancaster, Graeme Iain, Siddique, Monowarul Mobin, Poss, Annelise, Pearson, Mackenzie, Satapati, Santhosh, Zhou, Heather, McLaren, David G, Previs, Stephen F, Chen, Ying, Qian, Ying, Petrov, Aleksandr, Wu, Margaret, Shen, Xiaolan, Yao, Jun, Nunes, Christian N, Howard, Andrew D, Wang, Liangsu, Erion, Mark D, Rutter, Jared, Holland, William L, Kelley, David E, Summers, Scott A

“…Ceramides contribute to the lipotoxicity that underlies diabetes, hepatic steatosis, and heart disease. By genetically engineering mice, we deleted the enzyme…”
Get full text

Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy by Myers, Robert W., Guan, Hong-Ping, Ehrhart, Juliann, Petrov, Aleksandr, Prahalada, Srinivasa, Tozzo, Effie, Yang, Xiaodong, Kurtz, Marc M., Trujillo, Maria, Trotter, Dinko Gonzalez, Feng, Danqing, Xu, Shiyao, Eiermann, George, Holahan, Marie A., Rubins, Daniel, Conarello, Stacey, Niu, Xiaoda, Souza, Sandra C., Miller, Corin, Liu, Jinqi, Lu, Ku, Feng, Wen, Li, Ying, Painter, Ronald E., Milligan, James A., He, Huaibing, Liu, Franklin, Ogawa, Aimie, Wisniewski, Douglas, Rohm, Rory J., Wang, Liyang, Bunzel, Michelle, Qian, Ying, Zhu, Wei, Wang, Hongwu, Bennet, Bindu, Scheuch, Lisa LaFranco, Fernandez, Guillermo E., Li, Cai, Klimas, Michael, Zhou, Gaochao, van Heek, Margaret, Biftu, Tesfaye, Weber, Ann, Kelley, David E., Thornberry, Nancy, Erion, Mark D., Kemp, Daniel M., Sebhat, Iyassu K.

“…5′-Adenosine monophosphate–activated protein kinase (AMPK) is a master regulator of energy homeostasis in eukaryotes. Despite three decades of investigation,…”
Get full text

Functionally selective signaling and broad metabolic benefits by novel insulin receptor partial agonists by Wu, Margaret, Carballo-Jane, Ester, Zhou, Haihong, Zafian, Peter, Dai, Ge, Liu, Mindy, Lao, Julie, Kelly, Terri, Shao, Dan, Gorski, Judith, Pissarnitski, Dmitri, Kekec, Ahmet, Chen, Ying, Previs, Stephen F., Scapin, Giovanna, Gomez-Llorente, Yacob, Hollingsworth, Scott A., Yan, Lin, Feng, Danqing, Huo, Pei, Walford, Geoffrey, Erion, Mark D., Kelley, David E., Lin, Songnian, Mu, James

“…Insulin analogs have been developed to treat diabetes with focus primarily on improving the time action profile without affecting ligand-receptor interaction…”
Get full text

Author Correction: Functionally selective signaling and broad metabolic benefits by novel insulin receptor partial agonists by Wu, Margaret, Carballo-Jane, Ester, Zhou, Haihong, Zafian, Peter, Dai, Ge, Liu, Mindy, Lao, Julie, Kelly, Terri, Shao, Dan, Gorski, Judith, Pissarnitski, Dmitri, Kekec, Ahmet, Chen, Ying, Previs, Stephen F., Scapin, Giovanna, Gomez-Llorente, Yacob, Hollingsworth, Scott A., Yan, Lin, Feng, Danqing, Huo, Pei, Walford, Geoffrey, Erion, Mark D., Kelley, David E., Lin, Songnian, Mu, James

Get full text

Glucagon receptor antagonism induces increased cholesterol absorption[S] by Guan, Hong-Ping, Yang, Xiaodong, Lu, Ku, Wang, Sheng-Ping, Castro-Perez, Jose M., Previs, Stephen, Wright, Michael, Shah, Vinit, Herath, Kithsiri, Xie, Dan, Szeto, Daphne, Forrest, Gail, Xiao, Jing Chen, Palyha, Oksana, Sun, Li-Ping, Andryuk, Paula J., Engel, Samuel S., Xiong, Yusheng, Lin, Songnian, Kelley, David E., Erion, Mark D., Davis, Harry R., Wang, Liangsu

“…Glucagon and insulin have opposing action in governing glucose homeostasis. In type 2 diabetes mellitus (T2DM), plasma glucagon is characteristically elevated,…”
Get full text

Free energy calculations to estimate ligand-binding affinities in structure-based drug design by Reddy, M Rami, Reddy, C Ravikumar, Rathore, R S, Erion, Mark D, Aparoy, P, Reddy, R Nageswara, Reddanna, P

“…Post-genomic era has led to the discovery of several new targets posing challenges for structure-based drug design efforts to identify lead compounds. Multiple…”
Get more information

Pharmacological AMPK activation induces transcriptional responses congruent to exercise in skeletal and cardiac muscle, adipose tissues and liver by Muise, Eric S, Guan, Hong-Ping, Liu, Jinqi, Nawrocki, Andrea R, Yang, Xiaodong, Wang, Chuanlin, Rodríguez, Carlos G, Zhou, Dan, Gorski, Judith N, Kurtz, Marc M, Feng, Danqing, Leavitt, Kenneth J, Wei, Lan, Wilkening, Robert R, Apgar, James M, Xu, Shiyao, Lu, Ku, Feng, Wen, Li, Ying, He, Huaibing, Previs, Stephen F, Shen, Xiaolan, van Heek, Margaret, Souza, Sandra C, Rosenbach, Mark J, Biftu, Tesfaye, Erion, Mark D, Kelley, David E, Kemp, Daniel M, Myers, Robert W, Sebhat, Iyassu K

“…Physical activity promotes metabolic and cardiovascular health benefits that derive in part from the transcriptional responses to exercise that occur within…”
Get full text

Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index by Erion, Mark D, Cable, Edward E, Ito, Bruce R, Jiang, Hongjian, Fujitaki, James M, Finn, Patricia D, Zhang, Bao-Hong, Hou, Jinzhao, Boyer, Serge H, van Poelje, Paul D, Linemeyer, David L

“…Despite efforts spanning four decades, the therapeutic potential of thyroid hormone receptor (TR) agonists as lipid-lowering and anti-obesity agents remains…”
Get full text

Advances in binding free energies calculations: QM/MM-based free energy perturbation method for drug design by Rathore, R S, Sumakanth, M, Reddy, M Siva, Reddanna, P, Rao, Allam Appa, Erion, Mark D, Reddy, M R

“…Multiple approaches have been devised and evaluated to computationally estimate binding free energies. Results using a recently developed Quantum Mechanics…”
Get more information

Discovery of Potent and Specific Fructose-1,6-Bisphosphatase Inhibitors and a Series of Orally-Bioavailable Phosphoramidase-Sensitive Prodrugs for the Treatment of Type 2 Diabetes by Dang, Qun, Kasibhatla, Srinivas Rao, Reddy, K. Raja, Jiang, Tao, Reddy, M. Rami, Potter, Scott C, Fujitaki, James M, van Poelje, Paul D, Huang, Jingwei, Lipscomb, William N, Erion, Mark D

“…Excessive glucose production by the liver coupled with decreased glucose uptake and metabolism by muscle, fat, and liver results in chronically elevated blood…”
Get full text

MB06322 (CS-917): A Potent and Selective Inhibitor of Fructose 1,6-Bisphosphatase for Controlling Gluconeogenesis in Type 2 Diabetes by Erion, Mark D., van Poelje, Paul D., Dang, Qun, Kasibhatla, Srinivas Rao, Potter, Scott C., Reddy, M. Rami, Reddy, K. Raja, Jiang, Tao, Lipscomb, William N.

“…In type 2 diabetes, the liver produces excessive amounts of glucose through the gluconeogenesis (GNG) pathway and consequently is partly responsible for the…”
Get full text

Prodrugs of Phosphates and Phosphonates by Hecker, Scott J, Erion, Mark D

Get full text

Inhibition of Fructose 1,6-Bisphosphatase Reduces Excessive Endogenous Glucose Production and Attenuates Hyperglycemia in Zucker Diabetic Fatty Rats by VAN POELJE, Paul D, POTTER, Scott C, CHANDRAMOULI, Visvanathan C, LANDAU, Bernard R, QUN DANG, ERION, Mark D

“…Inhibition of Fructose 1,6-Bisphosphatase Reduces Excessive Endogenous Glucose Production and Attenuates Hyperglycemia in Zucker Diabetic Fatty Rats Paul D…”
Get full text

Liver-targeted drug delivery using HepDirect prodrugs by Erion, Mark D, van Poelje, Paul D, Mackenna, Deidre A, Colby, Timothy J, Montag, Annika C, Fujitaki, James M, Linemeyer, David L, Bullough, David A

“…Targeting drugs to specific organs, tissues, or cells is an attractive strategy for enhancing drug efficacy and reducing side effects. Drug carriers such as…”
Get more information

Antiviral Efficacy upon Administration of a HepDirect Prodrug of 2′-C-Methylcytidine to Hepatitis C Virus-Infected Chimpanzees by CARROLL, Steven S, KOEPLINGER, Kenneth, FUJITAKI, James M, BOYER, Serge H, LINEMEYER, David L, HECKER, Scott J, ERION, Mark D, VAVREK, Marissa, NANYAN RENA ZHANG, HANDT, Laurence, MACCOSS, Malcolm, OLSEN, David B, RAJA REDDY, K, ZHILI SUN, VAN POELJE, Paul D

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

A Long-Acting PYY 3-36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates by Rangwala, Shamina M, D'Aquino, Katharine, Zhang, Yue-Mei, Bader, Lindsay, Edwards, Wilson, Zheng, Songmao, Eckardt, Annette, Lacombe, Ann, Pick, Rebecca, Moreno, Veronica, Kang, Lijuan, Jian, Wenying, Arnoult, Eric, Case, Martin, Jenkinson, Celia, Chi, Ellen, Swanson, Ronald V, Kievit, Paul, Grove, Kevin, Macielag, Mark, Erion, Mark D, SinhaRoy, Ranabir, Leonard, James N

“…The gut hormone PYY reduces food intake in humans and exhibits at least additive efficacy in combination with GLP-1. However, the utility of PYY analogs as…”
Get full text

A Long-Acting PYY3–36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates by Rangwala, Shamina M., D’Aquino, Katharine, Zhang, Yue-Mei, Bader, Lindsay, Edwards, Wilson, Zheng, Songmao, Eckardt, Annette, Lacombe, Ann, Pick, Rebecca, Moreno, Veronica, Kang, Lijuan, Jian, Wenying, Arnoult, Eric, Case, Martin, Jenkinson, Celia, Chi, Ellen, Swanson, Ronald V., Kievit, Paul, Grove, Kevin, Macielag, Mark, Erion, Mark D., SinhaRoy, Ranabir, Leonard, James N.

“…The gut hormone PYY3–36 reduces food intake in humans and exhibits at least additive efficacy in combination with GLP-1. However, the utility of PYY analogs as…”
Get full text

Preclinical Pharmacokinetics of a HepDirect Prodrug of a Novel Phosphonate-Containing Thyroid Hormone Receptor Agonist by Fujitaki, James M, Cable, Edward E, Ito, Bruce R, Zhang, Bao-Hong, Hou, Jinzhao, Yang, Chun, Bullough, David A, Ferrero, James L, van Poelje, Paul D, Linemeyer, David L, Erion, Mark D

“…The prodrug [(2 R ,4 S )-4-(3-chlorophenyl)-2-[(3,5-dimethyl-4-(4′-hydroxy-3′-isopropylbenzyl)phenoxy)methyl]-2-oxido-[1,3,2]-dioxaphosphonane (MB07811)]…”
Get full text

Discovery of a Series of Phosphonic Acid-Containing Thiazoles and Orally Bioavailable Diamide Prodrugs That Lower Glucose in Diabetic Animals Through Inhibition of Fructose-1,6-Bisphosphatase by Dang, Qun, Liu, Yan, Cashion, Daniel K, Kasibhatla, Srinivas Rao, Jiang, Tao, Taplin, Frank, Jacintho, Jason D, Li, Haiqing, Sun, Zhili, Fan, Yi, DaRe, Jay, Tian, Feng, Li, Wenyu, Gibson, Tony, Lemus, Robert, van Poelje, Paul D, Potter, Scott C, Erion, Mark D

“…Oral delivery of previously disclosed purine and benzimidazole fructose-1,6-bisphosphatase (FBPase) inhibitors via prodrugs failed, which was likely due to…”
Get full text

Discovery of Insulin Receptor Partial Agonists MK-5160 and MK-1092 as Novel Basal Insulins with Potential to Improve Therapeutic Index by Pissarnitski, Dmitri A, Kekec, Ahmet, Yan, Lin, Zhu, Yuping, Feng, Danqing D, Huo, Pei, Madsen-Duggan, Christina, Moyes, Christopher R, Nargund, Ravi P, Kelly, Terri, Zhang, Xiaoping, Carballo-Jane, Ester, Gorski, Judith, Zafian, Peter, Qatanani, Mo, Kaarsholm, Niels, Meng, Fanyu, Jia, Xiujuan, Lee, Keun-Joong, Wang, Weixun, Xu, Sherrie, Hohn, Michael J, Iammarino, Michael J, McCoy, Mark A, Okoh, Grace A, Liang, Yingkai, Hollingsworth, Scott A, Erion, Mark D, Kelley, David E, Garbaccio, Robert M, Zhang, Amy, Mu, James, Lin, Songnian

“…We have identified a series of novel insulin receptor partial agonists (IRPAs) with a potential to mitigate the risk of hypoglycemia associated with the use of…”
Get full text